1. Coronavirus vaccine: How close are we to finding one? Here's what's happening  CNET
  2. Bharat Biotech's indigenous COVID-19 vaccine 'COVAXIN' gets approval  WION
  3. China's military approves coronavirus vaccine for use on soldiers  New York Post
  4. China’s Vaccine, TikTok, Pakistan Stock Exchange: Your Tuesday Briefing  The New York Times
  5. 'I just want this to be solved already': 30,000 sign up to be infected with coronavirus  WZTV
  6. View Full Coverage on Google News
Vaccines to prevent COVID-19 are being developed at a record clip. We tell you everything you need to know about today's progress against the potentially fatal disease.Vaccines to prevent COVID-19 are being developed at a record clip. We tell you everything you need to know about today's progress against the potentially fatal disease.

Coronavirus vaccine: How close are we to finding one? Here's what's happening - CNET

Drug Controller General of India approves Bharat Biotech's Covaxin for clinical human trials which will start in July.Drug Controller General of India approves Bharat Biotech's Covaxin for clinical human trials which will start in July.

India's first COVID-19 vaccine candidate cleared for human trials | India News | Al Jazeera

This is the first Indian vaccine and developed from a weakened strain of the virus isolated locally.This is the first Indian vaccine and developed from a weakened strain of the virus isolated locally.

Covaxin: India to hold human trial of coronavirus vaccine in July - BBC News

India's first vaccine candidate against COVID-19, named COVAXIN, has received approval from the Drug Controller General of India (DCGI) to conduct Phase I and Phase II trials on human beingsIndia's first vaccine candidate against COVID-19, named COVAXIN, has received approval from the Drug Controller General of India (DCGI) to conduct Phase I and Phase II trials on human beings

Breaking! India's first coronavirus vaccine candidate approved for human trials; details inside - Tamil News - IndiaGlitz.com

Bharat Biotech gets DGCI's approval for clinical trials of potential Covid-19 vaccine. | OpIndia NewsBharat Biotech gets DGCI's approval for clinical trials of potential Covid-19 vaccine. | OpIndia News

Bharat Biotech's potential vaccine for coronavirus enters clinical trial

The country's ‘first' indigenous COVID-19 vaccine COVAXIN, is all set for for human clinical trials as the global vaccine race kicks up another notch.COVAXIN, developed by city-based Bharat Biotech in collaboration with ICMR and NIV will undergo Human clinical trials across India in July 2020.The country's ‘first' indigenous COVID-19 vaccine COVAXIN, is all set for for human clinical trials as the global vaccine race kicks up another notch.COVAXIN, developed by city-based Bharat Biotech in collaboration with ICMR and NIV will undergo Human clinical trials across India in July 2020.

Are we close to a coronavirus vaccine? All you need to know - Oneindia News

Drug Controller General of India (DCGI) has approved Covid-19 vaccine developed by Hyderabad vaccine major Bharat Biotech. The firm announced that its COVAXIN has become the country’s first COVID vaccine candidate to get approval for phase one and two human clinical trials from DGCI. The company has been working on the vaccine in collaboration with the Indian Council of Medical Research and National Institute of Virology, Pune for some time, as reported by Times of India earlier. Bharat Biotech is simultaneously working on nasal vaccine CoroFlu against Covid-19 in collaboration with American researchers of the University of Wisconsin, Madison. Drug Controller General of India (DCGI) has approved Covid-19 vaccine developed by Hyderabad vaccine major Bharat Biotech. The firm announced that its COVAXIN has become the country’s first COVID vaccine candidate to get approval for phase one and two human clinical trials from DGCI. The company has been working on the vaccine in collaboration with the Indian Council of Medical Research and National Institute of Virology, Pune for some time, as reported by Times of India earlier. Bharat Biotech is simultaneously working on nasal vaccine CoroFlu against Covid-19 in collaboration with American researchers of the University of Wisconsin, Madison.

COVID-19: Hyderabad firm develops India’s first vaccine candidate, gets DCGI nod for human trials | City - Times of India Videos

Get the latest news from India and world with News On AIR. Find all news related covid 19 in india, coronavirus news update, breaking news, Politics news, Sports news, Business news, Arts and Entertainment news.

News On AIR - News Services Division, All India Radio News

30,000 people across the globe have signed up to purposely be exposed to novel coronavirus in the hopes it will speed up development of a vaccine against COVID-19. The announcement comes from 1 Day Sooner, a challenge trial advocacy group. Challenge trials -also referred to as challenge studies, involve the intentional infection of research participants in an effort to provide data on the effectiveness of vaccines and therapeutics. Challenge trials have been used for influenza and other studies.30,000 people across the globe have signed up to purposely be exposed to novel coronavirus in the hopes it will speed up development of a vaccine against COVID-19. The announcement comes from 1 Day Sooner, a challenge trial advocacy group. Challenge trials -also referred to as challenge studies, involve the intentional infection of research participants in an effort to provide data on the effectiveness of vaccines and therapeutics. Challenge trials have been used for influenza and other studies.

'I just want this to be solved already': 30,000 sign up to be infected with coronavirus | WZTV

'I just want this to be solved already': 30,000 sign up to be infected with coronavirus

The country's 'first' indigenous COVID-19 vaccine COVAXIN, developed by city-based Bharat Biotech in collaboration with ICMR and NIV, has got the nod for human clinical trials from the Drug Controller General of India, the company said on Monday.The country's 'first' indigenous COVID-19 vaccine COVAXIN, developed by city-based Bharat Biotech in collaboration with ICMR and NIV, has got the nod for human clinical trials from the Drug Controller General of India, the company said on Monday.

India’s 'First' Indigenous COVID-19 Vaccine COVAXIN Gets Approval For Human Clinical Trial

Hyderabad-based Bharat Biotech announced that it has successfully developed Covaxin, India's first vaccine candidate for Covid-19, in collaboration withHyderabad-based Bharat Biotech announced that it has successfully developed Covaxin, India's first vaccine candidate for Covid-19, in collaboration with

Hyd Company Announces India's First Covid-19 Vaccine - Gulte

Johnson & Johnson is preparing the ground for the entry of a vaccine against COVID-19 and is expanding its manufacturing capacity to supply more than one billion doses through 2021 in a not-for-profit project aimed at the common person, says its top scientist.Johnson & Johnson is preparing the ground for the entry of a vaccine against COVID-19 and is expanding its manufacturing capacity to supply more than one billion doses through 2021 in a not-for-profit project aimed at the common person, says its top scientist.

Johnson & Johnson Ramps Up Affordable COVID Vaccine Production, Human Trials Soon: Scientist

Permission granted after results demonstrate safety and ability to generate an immune responsePermission granted after results demonstrate safety and ability to generate an immune response

Coronavirus outbreak: Human safety trials for Indian vaccine - Telegraph India

Human clinical trials are scheduled to begin in India next month for the vaccine, which was developed and manufactured in Bharat BiotechHuman clinical trials are scheduled to begin in India next month for the vaccine, which was developed and manufactured in Bharat Biotech

Covaxin: COVID-19 vaccine candidate cleared for human trials  |

The human trials of this vaccine candidate for COVID-19, indigenously developed in collaboration with ICMR-NIV, will start across India in July 2020

COVAXIN from Bharat Biotech gets DCGI approval for Phase I & II Human Clinical Trials - Express Pharma

Bharat Biotech in India has secured regulatory approval from the DCGI to advance its Covid-19 vaccine candidate, Covaxin, into human clinical trials.Bharat Biotech in India has secured regulatory approval from the DCGI to advance its Covid-19 vaccine candidate, Covaxin, into human clinical trials.

First Covid-19 vaccine by Bharat Biotech to enter trials in India

A potential COVID-19 vaccine, the first to be developed in India, has been given approval by DCGI (Drug Controller General of India).A potential COVID-19 vaccine, the first to be developed in India, has been given approval by DCGI (Drug Controller General of India).

India's 1st COVID-19 Vaccine Set for Human Trials

Bharat Biotech, a leading vaccine and bio-therapeutics manufacturers is all geared up to conduct human clinical trials in July with Covaxin to battle the coronavirus. Covaxin had earlier been developed in Hyderabad at the Genome Valley plant, in collaboration with the Indian Council of Medical Research (ICMR).Krishna Ella, Chairperson and Managing Director of Bharat Biotech had made the announcement stating that the collaboration with ICMR and NIV has been instrumental in developing Covaxin. Furthermore, the support and the guidance from CDSCO had enabled approvals to the project, Ella stated.On Monday, June 29, the Hyderabad-based firm announced that the Drug Controller General of India (DGI) gave the green light for phase-1 and phase-2 human clinical trials of the indigenously developed drug. The company had earlier submitted results generated from pre-clinical (animal) studies to get approval to conduct human clinical trials. These trials are meant to demonstrate safety and immune responses.The SARS-CoV-2 strain was isolated at National Institute of Virology (Pune), an institute under the ICMR, and was transferred to Bharat Biotech. The company has a biosafety level-3 plant in the city of Hyderabad. These type of plants are conducive for work involving microbes, which could cause serious and potentially lethal diseases, through the inhalation route.In the wake of the coronavirus, in what seems to be a major breakthrough in finding a successful treatment for the disease, scientists at Oxford University had earlier reached a consensus that the low-dose usage of ‘dexamethasone’, can be used to reduce death rates in severely affected patients suffering from coronavirus. The drug is said to cut the risk of death by a third for patients on ventilators. For those on oxygen, it cut deaths by a fifth.While the country is witnessing a surge in the number of coronavirus cases every day, newer and more efficient drugs have been proving to be useful for treating COVID-19.Bharat Biotech, a leading vaccine and bio-therapeutics manufacturers is all geared up to conduct human clinical trials in July with Covaxin to battle the coronavirus. Covaxin had earlier been developed in Hyderabad at the Genome Valley plant, in collaboration with the Indian Council of Medical Research (ICMR).Krishna Ella, Chairperson and Managing Director of Bharat Biotech had made the announcement stating that the collaboration with ICMR and NIV has been instrumental in developing Covaxin. Furthermore, the support and the guidance from CDSCO had enabled approvals to the project, Ella stated.On Monday, June 29, the Hyderabad-based firm announced that the Drug Controller General of India (DGI) gave the green light for phase-1 and phase-2 human clinical trials of the indigenously developed drug. The company had earlier submitted results generated from pre-clinical (animal) studies to get approval to conduct human clinical trials. These trials are meant to demonstrate safety and immune responses.The SARS-CoV-2 strain was isolated at National Institute of Virology (Pune), an institute under the ICMR, and was transferred to Bharat Biotech. The company has a biosafety level-3 plant in the city of Hyderabad. These type of plants are conducive for work involving microbes, which could cause serious and potentially lethal diseases, through the inhalation route.In the wake of the coronavirus, in what seems to be a major breakthrough in finding a successful treatment for the disease, scientists at Oxford University had earlier reached a consensus that the low-dose usage of ‘dexamethasone’, can be used to reduce death rates in severely affected patients suffering from coronavirus. The drug is said to cut the risk of death by a third for patients on ventilators. For those on oxygen, it cut deaths by a fifth.While the country is witnessing a surge in the number of coronavirus cases every day, newer and more efficient drugs have been proving to be useful for treating COVID-19.

Coronavirus: Bharat Biotech gets approval to conduct human trials for vaccine | Mumbai

COVAXIN is India’s 'first' indigenous COVID-19 vaccine, developed by Hyderabad-based Bharat Biotech in collaboration with ICMR and NIVCOVAXIN is India’s 'first' indigenous COVID-19 vaccine, developed by Hyderabad-based Bharat Biotech in collaboration with ICMR and NIV

India's first COVID-19 vaccine COVAXIN: Here is everything you want to know - Moneycontrol.com

Hyderabad based Bharat Biotech is the first Indian company which has received a go-ahead to start the clinical trials.Hyderabad based Bharat Biotech is the first Indian company which has received a go-ahead to start the clinical trials.

Coronavirus vaccine update: Bharat Biotech's starts clinical trials, Chinese vaccine Sinovac wins military approval and more updates about COVID-19 | The Times of India

The vaccine was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research and National Institute of Virology. The vaccine was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research and National Institute of Virology.

Coronavirus: Hyderabad company’s vaccine is India’s first to get approval for human clinical trials

The vaccine was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research and National Institute of Virology. The vaccine was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research and National Institute of Virology.

Coronavirus: Hyderabad company’s vaccine is India’s first to get approval for human clinical trials

The SARS-CoV-2 strain was isolated in NIV and transferred to Bharat Biotech, which has developed the indigenous, inactivated vaccine at its biosafety level-3 (BSL-3) high containment facility located in Genome Valley in Hyderabad outskirts.

Bharat Biotech’s Covid vaccine gets DCGI nod for clinical trials - The Economic Times

 India’s drug regulator has granted approval for clinical trials of the first indigenously developed vaccine candidate against Covid-19. The vaccine candidate Covaxin is developed by Bharat Biotech using the Covid-19 genome isolated by the National Institute of Virology, a Pune-based research facility under the aegis of Indian Council of Medical Research. “We are proud to India’s drug regulator has granted approval for clinical trials of the first indigenously developed vaccine candidate against Covid-19. The vaccine candidate Covaxin is developed by Bharat Biotech

India's first Covid-19 vaccine candidate gets nod for human clinical trials | Deccan Herald

Bharat Biotech's indigenous COVID-19 vaccine 'COVAXIN' gets approval for phase I & II human clinical trials - The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous inactivated vaccine was developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad.Bharat Biotech's indigenous COVID-19 vaccine 'COVAXIN' gets approval for phase I & II human clinical trials - The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous inactivated vaccine was developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad.

Bharat Biotech's indigenous COVID-19 vaccine 'COVAXIN' gets approval for phase I & II human clinical trials

india first coronavirus vaccine, India's first COVID-19 vaccine COVAXIN, COVAXIN gets DCGI nod, coronavirus vaccine human clinical trial, COVAXIN India’s first COVID-19 vaccine - COVAXIN, developed by Bharat Biotech in collaboration with the ICMR - National Institute of Virology (NIV) gets nod from Drugs Controller General of India (DCGI) for human clinical trials.

India's first COVID-19 vaccine candidate COVAXIN gets DCGI nod for human clinical trials | India News – India TV

After successfully testing animals, Union Ministry of Health & Family Welfare has now approved clinical human trials for India's first COVID-19 vaccine-Covaxin.After successfully testing animals, Union Ministry of Health & Family Welfare has now approved clinical human trials for India's first COVID-19 vaccine-Covaxin.

Centre approves human trials for India's Covid-19 vaccine from July - Republic World

Hindustan TimesHindustan Times’ National Political Editor, Sunetra Choudhury brings you the top stories you need to know. Sunetra talks about the number of covid-19 cases in India, what you can’t do in Unlock 2, how monsoon session of parliament will happen, India’s first covid vaccine candidate Covaxin approved for human trials and more. Watch the video for more details.Hindustan TimesHindustan Times’ National Political Editor, Sunetra Choudhury brings you the top stories you need to know. Sunetra talks about the number of covid-19 cases in India, what you can’t do in Unlock 2, how monsoon session of parliament will happen, India’s first covid vaccine candidate Covaxin approved for human trials and more. Watch the video for more details.

India’s first covid vaccine candidate Covaxin approved for human trials - coronavirus-crisis - videos - Hindustan Times

Trials for the Bharat Biotech developed Covaxin to start across the country in JulyTrials for the Bharat Biotech developed Covaxin to start across the country in July

India's first Covid-19 vaccine candidate approved for human trials - News | Khaleej Times

M Somasekhar Hyderabad: India has joined the ‘hot race’ to develop a potential COVID-19 vaccine with a significant announcement that a consortia has gotM Somasekhar Hyderabad: India has joined the ‘hot race’ to develop a potential COVID-19 vaccine with a significant announcement that a consortia has got

Consortia led by Hyd's Bharat Biotech to begin human trials of COVID vaccine soon

The DGCI has approved the company’s application to conduct a phase I and II clinical trial of its vaccine candidate ‘Covaxin’.While there are multiple vaccine trials ongoing in India, including those of candidates by Zydus Cadila, Serum Institute of India and Panacea Biotec, all of them are in pre-clinical stage as of nowThe DGCI has approved the company’s application to conduct a phase I and II clinical trial of its vaccine candidate ‘Covaxin’.While there are multiple vaccine trials ongoing in India, including those of candidates by Zydus Cadila, Serum Institute of India and Panacea Biotec, all of them are in pre-clinical stage as of now

Bharat Biotech’s Covid-19 vaccine first in India to receive nod for human trials

Bharat Biotech’s coronavirus vaccine Covaxin is the first COVID-19 vaccine to get DGCI’s (Drug Controller General of India) nod. The drug regulatory body allowedBharat Biotech’s coronavirus vaccine Covaxin is the first COVID-19 vaccine to get DGCI’s (Drug Controller General of India) nod. The drug regulatory body allowed

An Indian COVID-19 vaccine made by Bharat Biotech is set to enter human trials | Business Insider India

Coronavirus vaccine update: The Hyderabad-based vaccine major's vaccine candidate COVAXIN has received permission for advancing to human trialsCoronavirus vaccine update: The Hyderabad-based vaccine major's vaccine candidate COVAXIN has received permission for advancing to human trials

Coronavirus vaccine update: India's first vaccine candidate COVAXIN to begin human trials in July

India Covid-19 vaccine candidate Covaxin, Bharat Biotech Coronavirus Vaccine: How does Covaxin compare to other vaccine candidates around the world? Where does it figure in the global race for a Covid-19 vaccine?India's Covid-19 vaccine candidate Covaxin: How does Covaxin compare to other vaccine candidates around the world? Where does it figure in the global race for a Covid-19 vaccine?

India Covid-19 vaccine candidate Covaxin: What is Covaxin and how was it developed? | Bharat Biotech Coronavirus Vaccine

Coronavirus vaccine, covid-19 vaccine, coronavirus vaccine india, Bharat Biotech’s Covid vaccine, india coronavirus vaccine, india covid-19 vaccine, india covid-19 vaccine icmr, icmr bbil coronavirus vaccine, first coronavirus vaccine in indiaThe recently developed coronavirus vaccine named COVAXIN, has got the approval for human trials by the Drug Controller General of India (DCGI).

COVID-19 Update: Bharat Biotech Develops India

Hyderabad based biotech company Bharat Biotech has got approval from DGCI to conduct phase 1 and 2 human trials for the Covid 19 vaccine candidate, Covaxin.Hyderabad based biotech company Bharat Biotech has got approval from DGCI to conduct phase 1 and 2 human trials for the Covid 19 vaccine candidate, Covaxin.

India’s First Covid 19 Vaccine Candidate, Covaxin By Bharat Biotech, Set To Begin Human Trials From July

Access Denied

Pharma major ``Bharat Biotech'' has announced development of COVAXIN™,  India’s 1st  vaccine candidate for COVID-19, in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad. Pharma major ``Bharat Biotech'' has announced development of COVAXIN™,  India’s 1st  vaccine candidate for COVID-19, in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad. 

Bharat Biotech announces DGCI's approval for its "COVAXIN" COVID-19 vaccine for Phase I & II human clinical trials, India News News | wionews.com

Hyderabad based pharmaceutical firm Bharat Biotech has developed India's first vaccine candidate for coronavirus. The company got approvals for the vaccine after submitting results generated from preclinical studies, demonstrating safety and immune response against Covid-19.Hyderabad based pharmaceutical firm Bharat Biotech has developed India's first vaccine candidate for coronavirus. The company got approvals for the vaccine after submitting results generated from preclinical studies, demonstrating safety and immune response against Covid-19.

India's first coronavirus vaccine gets nod for human trials - India News

Hyderabad, June 30: COVAXIN, India's first vaccine against the novel coronavirus, developed by Bharat Biotech, Hyderbad-based biotechnology firm in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), gets nod from the Drug ControllerHyderabad, June 30: COVAXIN, India's first vaccine against the novel coronavirus, developed by Bharat Biotech, Hyderbad-based biotechnology firm in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), gets nod from the Drug Controller

COVAXIN: India's first COVID-19 vaccine developed by Bharat Biotech gets nod for human trials

Bharat Biotech has developed India’s first vaccine candidate for Covid-19, Covaxin, in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV).The Drug CoBharat Biotech has developed India’s first vaccine candidate for Covid-19, Covaxin, in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV).The Drug Co

DCGI approves Bharat Biotech’s Covid-19 vaccine for human clinical trials - The Hindu BusinessLine

The Phase I and Phase II clinical trials of the vaccine for SARS-CoV-2 would start across the country next month.The Phase I and Phase II clinical trials of the vaccine for SARS-CoV-2 would start across the country next month.

India's First Coronavirus Vaccine Candidate 'Covaxin' Gets Nod For Human Clinical Trials

Hyderabad (Telangana) [India], June 30 (ANI): Hyderabad-based Bharat Biotech announced that it has successfully developed Covaxin, India's first vaccine candidate for Covid-19, in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).Hyderabad (Telangana) [India], June 30 (ANI): Hyderabad-based Bharat Biotech announced that it has successfully developed Covaxin, India's first vaccine candidate for Covid-19, in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).

Bharat Biotech announces India's first COVID-19 vaccine candidate 'COVAXIN' with DCGI approval for human clinical trials

India’s first COVID-19 vaccine candidate COVAXIN has received the approval of drug regulator DGCI for phase I and II of human clinical trials. The drug has been developed by Bharat Biotech.Get latest Healthcare online at cnbctv18.com India’s first COVID-19 vaccine candidate COVAXIN has received the approval of drug regulator DGCI for phase I and II of human clinical trials. The drug has been developed by Bharat Biotech.Get latest Healthcare online at cnbctv18.com

India’s first COVID-19 vaccine candidate COVAXIN gets DCGI approval; human trials to begin in July - cnbctv18.com

COVAXIN, India’s first vaccine candidate against novel coronavirus, developed by vaccine maker Bharat Biotech gets the approval of DCGI for Phase I and II clinical trials.COVAXIN, India’s first vaccine candidate against novel coronavirus, developed by vaccine maker Bharat Biotech gets the approval of DCGI for Phase I and II clinical trials.

Bharat Biotech, has successfully developed COVAXIN, India’s 1st vaccine candidate for COVID-19, in collaboration with the ICMR and National Institute of Virology.Bharat Biotech, has successfully developed COVAXIN, India’s 1st vaccine candidate for COVID-19, in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech.

COVAXIN-India’s 1st COVID-19 vaccine candidate gets DCGI nod for human trials